NASDAQ:ATYR

aTyr Pharma Q3 2026 Earnings Results & Report

aTyr Pharma logo
$3.96 -0.13 (-3.06%)
As of 02:43 PM Eastern
This is a fair market value price provided by Massive. Learn more.

aTyr Pharma missed analyst earnings expectations in its Q3 2026 results, released November 6, 2026. The company reported EPS of -$7.43 versus the -$4.00 consensus estimate.

Earnings Announcement Details

Quarter
Q3 2026
Report Date
Time
After Market Closes
Conference Call Date
Conference Call
4:00 PM ET

aTyr Pharma EPS Results

Actual EPS
-$7.43
Consensus EPS
-$4.00
Beat/Miss
Missed by -$3.43
One Year Ago EPS
N/A
EPS Beat Rate
5 of last 8 quarters

aTyr Pharma Revenue Results

Actual Revenue
N/A
Expected Revenue
$2.50 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

aTyr Pharma Q3 2026 Earnings FAQ

aTyr Pharma (NASDAQ:ATYR) reported earnings of -$7.43 per share for Q3 2026, missing the consensus estimate of -$4.00. The report was announced on Friday, November 6, 2026.

aTyr Pharma Earnings Headlines

Today's free pick (on me)
Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one lesser known company. With plans filed for 1,000,000 new satellites, that licensing fee could scale dramatically. Analyst Dylan says the stock could move by December 8th.tc pixel
aTyr Pharma (NASDAQ:ATYR) Stock Rating Lowered by Wall Street Zen
FY2026 EPS Estimate for aTyr Pharma Reduced by Analyst
See More aTyr Pharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like aTyr Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on aTyr Pharma and other key companies, straight to your email.

About aTyr Pharma

aTyr Pharma (NASDAQ:ATYR) is a clinical-stage biotechnology company focused on developing medicines based on the extracellular biology of tRNA synthetases, a family of proteins involved in cellular processes. The company is headquartered in San Diego, California.

Its lead drug candidate, efzofitimod, is an immunomodulator being studied for pulmonary sarcoidosis and other interstitial lung diseases. The candidate is designed to act through neuropilin-2, a receptor involved in immune regulation.

aTyr’s research programs draw on its work in tRNA synthetase biology, with the broader goal of developing treatments for inflammatory and fibrotic conditions. Its activities center on drug research and clinical development.

View aTyr Pharma Profile